| 前收市價 | 0.3200 |
| 開市 | 0.1700 |
| 買盤 | 0.0100 |
| 賣出價 | 0.5200 |
| 拍板 | 705.00 |
| 到期日 | 2024-06-07 |
| 今日波幅 | 0.1700 - 0.1700 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 82 |
ReutersLilly invests further $5.3 billion in new Indiana site as obesity drug demand soars
(Reuters) -Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana manufacturing plant, more than doubling its previous investment, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs. The new investment, which brings the total to $9 billion, will help boost production of the active pharmaceutical ingredients (API) for Lilly's powerful weight-loss drug Zepbound and diabetes treatment Mounjaro, the company said. “Today’s announcement tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history,” said Lilly CEO David Ricks.
ZacksPharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
Motley Fool3 Blue Chip Stocks That You Can Buy and Hold for Years
You won't be taking on much risk by investing in these stalwarts.
